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Abstract
Killer cell immunoglobulin-like receptors (KIRs) influence both innate and adaptive immunity. But while the role of KIRs in
NK-mediated innate immunity is well-documented, the impact of KIRs on the T cell response in human disease is not known.
Here we test the hypothesis that an individual’s KIR genotype affects the efficiency of their HLA class I-mediated antiviral
immune response and the outcome of viral infection. We show that, in two unrelated viral infections, hepatitis C virus and
human T lymphotropic virus type 1, possession of the KIR2DL2 gene enhanced both protective and detrimental HLA class I-
restricted anti-viral immunity. These results reveal a novel role for inhibitory KIRs. We conclude that inhibitory KIRs, in
synergy with T cells, are a major determinant of the outcome of persistent viral infection.
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Introduction
Killer cell immunoglobulin-like receptors (KIRs) are a family of
transmembrane proteins that are expressed on natural killer (NK)
cells and subsets of T cells [1–3]. They bind HLA class I molecules
and have activatory and inhibitory isoforms [4]. KIRs contribute
directly and indirectly to antiviral immunity. Directly, KIRs on
NK cells sense the loss of HLA class I molecules from the cell
surface and trigger NK-mediated cytolysis. Indirectly, NK cells
regulate adaptive immunity via crosstalk with dendritic cells and
by the production of chemokines and cytokines [5–7].
HLA class I molecules can be grouped into allotypes with
similar KIR binding properties [8]. For example, KIR2DL2 binds
group C1 HLA-C molecules which have asparagine at residue 80,
and, with a weaker affinity, group C2 molecules which have a
lysine at position 80 [9].
Early research on KIRs investigated NK-mediated protection
by studying disease associations with KIRs in the context of their
HLA class I ligands [10–11]. There is now compelling evidence
that KIRs also regulate adaptive immunity [5–7], but it is not
known whether this has a significant impact on the response to
infection in vivo. Differences between human KIRs and their
mouse functional homologues (the Ly49 receptors) and the paucity
of KIR allele-specific antibodies have hindered work on the role of
KIRs in controlling adaptive immune responses. Here we used
immunogenetics to investigate whether KIR genotype modulates
HLA-mediated anti-viral protection in vivo. We focussed on HLA
class I alleles which have previously been associated with disease
outcome and investigated whether these effects were altered by the
KIR background. We studied 4 well-documented HLA class I
allele-disease associations in two viral infections: human T
lymphotropic virus type 1 (HTLV-1) and hepatitis C virus (HCV).
HTLV-1 is a persistent retrovirus that infects 10–20 million
people worldwide. Most infected individuals remain lifelong
asymptomatic carriers (ACs). However, approximately 10% of
infected individuals develop associated diseases including HTLV-
1-associated myelopathy/tropical spastic paraparesis (HAM/
TSP), an inflammatory disease of the central nervous system that
results in progressive paralysis. It is poorly understood why some
individuals remain asymptomatic whereas others develop disease,
but one strong correlate of disease is the proviral load, which is
significantly higher in HAM/TSP patients than in ACs [12]. We
have previously shown that HLA-A*02 and C*08 are each
associated with both a reduced risk of HAM/TSP and a reduced
proviral load in ACs and that HLA-B*54 is associated with an
increased prevalence of HAM/TSP and an increased proviral load
in HAM/TSP patients [13–14].
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HCV is among the most widespread viral infections, with 170
million infected people worldwide. As in HTLV-1 infection, the
outcome of HCV infection is heterogeneous: the virus persists in
approximately 70% of infected individuals while the rest clear the
infection spontaneously. Chronic HCV infection can cause serious
liver damage including cirrhosis and hepatocellular carcinoma
[15]. The origins of this heterogeneity are not completely
understood but several genetic determinants have been identified,
including HLA-B*57 which is associated with spontaneous
clearance in several cohorts [16–19].
The aim of this study was to test the hypothesis that KIR
genotype determines the efficiency of HLA class I-mediated anti-
viral immunity. We tested this hypothesis for 4 HLA class I
associations: HLA-C*08, A*02 and B*54 in HTLV-1 infection and
B*57 in HCV infection. We show, using multiple independent
measures, that for both HCV and HTLV-1, possession of the
KIR2DL2 gene enhanced HLA class I-restricted immunity.
Results
Two independent cohorts were studied: HCV-infected individ-
uals (N= 782) and HTLV-1-infected individuals (N= 402). Ten
KIR genes were typed; of these, 4 were present at an informative
frequency in the HTLV-1 cohort and 9 in the HCV cohort
(defined in Methods). The modulation of HLA class I associations
by the informative KIRs was analysed; the models included all
other known determinants of outcome in the cohorts as covariates.
HTLV-1 and disease status
In the cohort from Southern Japan, HLA-C*08 was associated
with a significantly reduced odds of developing HAM/TSP (OR=
0.47, p= 0.03, OR,1 indicates a protective effect while OR.1
indicates a detrimental effect)[14]. We investigated the impact of
KIRs on this protective effect by stratifying the cohort by KIR
Author Summary
Hepatitis C virus (HCV) and human T-cell leukemia virus
(HTLV-I) infect millions of people worldwide. Some HCV-
infected individuals spontaneously clear the virus and
many HTLV-1-infected people remain asymptomatic;
however, in both cases the infection can lead to serious
illness such as cancer. The factors which determine
outcome are still elusive. We have found that a gene that
encodes a receptor (KIR2DL2) enhances both protective
and detrimental HLA class I-mediated immunity to HCV
and HTLV-1. Strikingly, although KIRs are primarily
associated with innate immunity, our observations suggest
that they also have a major impact on the efficiency of the
adaptive immune response. This work helps to explain
why one individual infected with a virus remains healthy
but another, infected with the same virus develops
disease; it also helps to explain why particular HLA class I
molecules do not always protect or cause susceptibility as
expected. Interestingly, the impact of the KIR is entirely
context dependent: if an HLA class I molecule is protective
then protection is enhanced, but in the context of a
detrimental HLA then susceptibility is enhanced. This study
reveals a novel role for inhibitory KIRs in adaptive
immunity.
Table 1. KIR2DL2 in HTLV-1 infection: KIR2DL2 enhances the protective effect of C*08 and the detrimental effect of B*54 on HAM/
TSP risk and, independently, on proviral load.
HTLV-1 disease status (HAM/TSP v AC)
OR in whole
cohort (p value) KIR2DL2 Genotype
OR in stratified
cohort (p value) HLA Allele Carriers Cohort size
C*08 0.470 (p = 0.03) + 0.160 (p = 0.02) 14 102
2 0.665 (p = 0.4) 44 300
B*54 3.106 (p = 0.0009) + 12.048 (p = 0.004) 21 102
2 1.701 (p = 0.2) 64 300
HTLV-1 proviral load
Difference in VL in
whole cohort (p value) KIR2DL2 Genotype
Difference in VL in
stratified cohort (p
value) HLA Allele Carriers Cohort size
C*08 AC 20.330 (p = 0.05) + 20.660 (p = 0.07) 10 48
2 20.286 (p = 0.2) 26 132
HAM/TSP 20.173 (p = 0.2) + 20.856 (p = 0.005) 4 54
2 20.087 (p = 0.6) 18 168
B*54 AC 0.057 (p = 0.8) + 20.218 (p = 0.7) 3 48
2 0.095 (p = 0.7) 21 132
HAM/TSP 0.240 (p = 0.01) + 0.417 (p = 0.01) 18 54
2 0.224 (p = 0.05) 43 168
In the disease status models an odds ratio (OR),1 indicates a protective effect (decreased risk of HAM/TSP), an OR.1 indicates a detrimental effect (increased risk of
HAM/TSP). In the proviral load models the dependent variable was log10[proviral load], a difference in VL,0 indicates a protective effect (decreased pvl with the HLA
allele), a difference in VL.0 indicates a detrimental effect (increased pvl with the HLA allele). All models also included the two variables which can act as confounding
variables in this cohort: age and gender. The impact on proviral load was considered separately in ACs and HAM/TSP and so the observation of an impact on proviral
load is independent of the observation of an impact on status. If variables which were not significant predictors (p,0.05) were removed by backwards stepwise
exclusion the conclusions were unchanged.
doi:10.1371/journal.ppat.1002270.t001
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Figure 1. KIR2DL2 enhances HLA class I mediated antiviral-immunity. The effect of both protective (Figure 1a) and detrimental (Figure 1b)
HLA class I alleles on both status (first column) and viral load (second column) is stronger in KIR2DL2+ individuals than in KIR2DL2- individuals. This
effect was seen in both HTLV-1 and HCV infection. We also saw a progressive effect of KIR2DL2 copy number on both status and viral load in HCV
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PLoS Pathogens | www.plospathogens.org 3 October 2011 | Volume 7 | Issue 10 | e1002270
genotype. Of the KIR studied, one particular KIR, KIR2DL2, had a
noticeable interaction with C*08 (Table 1 and Figure 1). We found
that the C*08 protective effect was weakened and no longer
statistically significant in the subset of individuals who were KIR2DL2-
(OR=0.67, p=0.4) but enhanced in KIR2DL2+ individuals
(OR=0.16, p=0.02). There were more KIR2DL2- individuals than
KIR2DL2+ individuals so the absence of significance in the KIR2DL2-
individuals was not simply due to reduced cohort size. Similarly,
HLA-B*54, which is associated with a significantly increased risk of
HAM/TSP (OR=3.11, p=0.0009), had a weakened impact on
disease risk in the absence of KIR2DL2 (OR=1.70, p=0.2) but an
enhanced impact in the presence of KIR2DL2 (OR=12.05,
p=0.004). Again, the absence of a significant effect of B*54 in
KIR2DL2- individuals was not attributable to a loss of power. In
contrast, although HLA-A*02 was associated with a reduced risk of
HAM/TSP, there was no significant additional impact of KIR
genotype which could not be attributed to power.
HTLV-1 and proviral load
As an independent test of the observation that KIR2DL2
enhanced the effect of both protective and detrimental HLA class I
alleles in HTLV-1 infection, we investigated the interaction
between HLA class I alleles, KIR2DL2 and HTLV-1 proviral load
(pvl). We investigated pvl in ACs and HAM/TSP patients
separately, so any observed impact on pvl is independent of the
impact on disease status. C*08 has previously been associated with
a low pvl in ACs (difference in log10 pvl between C*08+ and C*08-
D=20.33, p = 0.05); again, this effect was weakened in KIR2DL2-
individuals (D=20.29 p= 0.2) but enhanced in KIR2DL2+
individuals (D=20.66 p= 0.07); Table 1. Similarly, HLA-B*54,
which is associated with a high pvl in HAM/TSP patients
(D= +0.24 p= 0.01) showed a weakened effect in the absence of
KIR2DL2 (D= +0.22, p = 0.05) but an enhanced effect in the
presence of KIR2DL2 (D= +0.42, p = 0.01).
Two previous observations on HTLV-1 immunogenetics have,
until now, remained unexplained. Firstly, although C*08 has been
associated with a low pvl in ACs it has no detectable impact on pvl
in HAM/TSP patients; similarly, B*54, which was associated with
a high pvl in HAM/TSP patients, had no impact on pvl in ACs
[13–14]. Why some HLA class I alleles apparently ‘‘cease
working’’ in some populations was unknown. We hypothesised
that the lack of the expected C*08 and B*54 effects in HAM/TSP
patients and ACs respectively was due to a low frequency of
KIR2DL2 in these groups and that the decrease or increase in pvl
due to C*08 or B*54 respectively would be manifest only in
KIR2DL2+ individuals. Consistent with this hypothesis we found
that the frequency of KIR2DL2 carriage in the groups that did not
show the expected effect of HLA genotype on pvl was
approximately half that of the groups in which HLA-associated
effects were observed (prevalence of KIR2DL2+ amongst B*54+
individuals: 12.5% in ACs vs 29.5% in HAM/TSPs; prevalence of
KIR2DL2+ amongst C*08+ individuals: 18.2% in HAM/TSPs vs
27.8% in ACs; Table 1). The small numbers of individuals in the
stratified cohorts (HAM/TSP KIR2DL2+: C*08+ N=4, C*08-
N=50. AC KIR2DL2+: B*54+ N=3, B*54- N=45) precluded a
reliable test for an impact of HLA on pvl in KIR2DL2+ individuals.
However, in the larger of these groups there was a significant
impact; i.e C*08 was associated with a significant reduction in pvl
in KIR2DL2+ individuals (D= -0.86, p= 0.005). This provides, for
the first time, a plausible explanation for the reported observation
[14] that the B*54 effect on pvl was not manifest in ACs and the
C*08 effect on pvl was not manifest in HAM/TSP patients.
HTLV-1 and HLA class I specificity
We recently reported that in HTLV-1 infection, HLA class I
molecules that bind peptides from the virus protein HBZ are
associated with a reduced risk of HAM/TSP and, independently, a
reduced pvl [20]. In the same study we showed, using IFNg ELISpot,
chromium release and CD107 staining, that HBZ-specific CD8+ T
cells were present and functional in fresh PBMC from infected
individuals. We therefore investigated the interaction between
KIR2DL2 and the protective effect of binding HBZ. We used epitope
prediction software [21] to predict the strength of binding of HBZ
peptides to an individual’s HLA-A and B molecules. We found that
ACs had HLA-A and -B molecules that are predicted to bind HBZ
significantly more strongly than those in HAM/TSP patients (median
difference 12%, p=0.00005) [20] and that this effect was stronger in
KIR2DL2+ individuals (median difference 25%, p=0.00006) than in
KIR2DL2- individuals (median difference 7%, p=0.06); Figure 2a.
We reasoned that this difference in HBZ binding between ACs and
HAM/TSP patients was due to HLA-A*02 and B*54, which differ in
their HBZ peptide-binding affinities [20] and are associated with
different outcomes in HTLV-1 infection. We therefore removed all
individuals with A*02 or B*54 from the cohort and repeated the
analysis. Surprisingly, we still found the same pattern: possession of
HLA molecules that bind HBZ strongly was significantly associated
with remaining asymptomatic (median difference 10%, p=0.04) and
this effect was strengthened in KIR2DL2+ individuals (median
difference 23%, p=0.02) but not in KIR2DL2- individuals (median
difference 3%, p=0.2); Figure 2b. This demonstrates that the
protective effect of binding HBZ peptides by multiple HLA class I
molecules, both A and B, is enhanced by KIR2DL2.
HCV and viral clearance
As previously reported, HLA-B*57 was associated with signifi-
cantly decreased odds of chronic infection (OR=0.571, p=0.02).
This protective effect was enhanced in the presence of KIR2DL2
(OR=0.40, p=0.007) but weakened in the absence of KIR2DL2
(OR=0.83, p=0.6) (Table 2). Furthermore, the impact of B*57 was
strongest in KIR2DL2 homozygote individuals (OR=0.21, p=0.02),
weaker in KIR2DL2 heterozygote individuals (OR=0.48, p=0.07)
and absent in KIR2DL2-negative individuals (OR=0.83, p=0.6).
KIR2DL2 enhanced the association between B*57 and spontaneous
clearance independently and with similar strength in both African
Americans and Caucasians (Table S1 in Text S1).
HCV and viral load
Next we investigated the impact of B*57 and KIR2DL2 on HCV
viral load. We only considered patients with chronic infection, so
any observed impact on viral load is independent of the impact on
viral clearance. This analysis was possible in two cohorts: MHCS
and ALIVE. We found that B*57 was associated with reduced
chronic HCV viral load, particularly in the MHCS cohort
(MHCS: difference in log10 VL D=23.1 p= 0.0003; ALIVE:
D=20.18 p= 0.3. Combined p= 0.0006). Consistent with our
observations in HTLV-1 infection, this reduction was enhanced in
the presence of KIR2DL2 (MHCS: D=24.5 p,0.0001, ALIVE:
D=20.46 p= 0.05. Combined p= 0.00003) but weakened in the
(Figure 1c). We could not test for a progressive effect in the HTLV-1 cohort because there are no KIR2DL2 homozygotes. In all cases, the impact on
viral burden was considered within (not between) disease status categories and so the observation of an impact on viral burden is independent of
the observation of an impact on status. Effect sizes, p values and cohort sizes are provided in Table 1.
doi:10.1371/journal.ppat.1002270.g001
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absence of KIR2DL2 (MHCS D=21.64 p= 0.2, ALIVE
D= +0.32 p= 0.3. Combined p= 0.7); Table 2 and Figure 3. In
MHCS (but not ALIVE) we also observed a progressive effect with
KIR2DL2 copy number (2 copies: D=26.5, p = 0.0005. 1 copy:
D=24.1 p= 0.001. 0 copies D=21.6 p= 0.2); the number of
homozygous individuals are too small to draw firm conclusions but
this progressive effect is consistent with our other observations.
These data show that KIR2DL2 enhances both protective and
detrimental HLA class I associations. Therefore, KIR2DL2 would
not be predicted to have a significant net impact across all HLA
class I molecules. That is, possession of KIR2DL2 (alone or with its
C1 ligand) without a particular protective or detrimental HLA
allele, would not be expected to be significantly protective or
detrimental. This prediction was verified (Table S2 in Text S1).
There is strong linkage disequilibrium among the KIR genes
and among the HLA class I genes. Analysis of the linked genes
indicates that the primary genes driving the observed associations
are most likely to be KIR2DL2 in combination with HLA-B*54,
C*08 and B*57 rather than individual linked KIR, multiple
stimulatory linked KIRs or linked HLA class I genes (sections 3
Figure 2. The protective effect of binding HBZ is enhanced by KIR2DL2. In the whole cohort (Figure 2a) individuals with HLA-A or B
molecules which were predicted to bind peptides from HBZ strongly were significantly more likely to be asymptomatic (top row); this effect was
stronger in the individuals with KIR2DL2 (middle row) than without (bottom row). When individuals with A*02 or B*54 were removed (Figure 2b) the
pattern remained the same. This indicates that the protective effect of binding HBZ peptides by multiple, different HLA class I molecules, both A and
B, is enhanced by KIR2DL2.We did not predict HLA-C binding as the relevant algorithms are not available in Metaserver (due to scarcity of HLA C
binding data necessary for training the neural networks).
doi:10.1371/journal.ppat.1002270.g002
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and 4 in Text S1). We cannot rule out an effect of linkage between
KIR2DL2 and neighbouring loci outside the KIR genes. However,
there is little evidence of significant linkage between KIRs and
even the next closest gene cluster, the LILR [22]. Furthermore, we
observed the same effect of KIR2DL2 in three different populations
(Japanese, African-American and Caucasian) so a putative linked
locus driving the effect would have to be linked to KIR2DL2 in all
three populations.
Canonical KIR-HLA binding
Although HLA-C*08, as a group C1 molecule, is expected to
bind KIR2DL2, the most frequent subtype in our cohort
(Cw*0801, 88%) binds KIR2DL2 very weakly (comparable to
background [23]), furthermore HLA-B*54 and HLA-B*57 are not
expected to bind KIR2DL2 and the most frequent subtypes in our
cohorts (B*5401 and B*5701) have been shown not to bind
KIR2DL2 [9,23]. Finally, KIR2DL2 enhanced the protective
effect of binding HBZ peptides by multiple HLA-A and –B
molecules. With the exception of B*4601 and B*7301 (which were
not responsible for the enhancement, data not shown) KIR2DL2 is
not thought to bind HLA-A and B molecules and has been shown
not to bind 29 HLA-A and 54 HLA-B allotypes [9]. We therefore
hypothesised that the effect of KIR2DL2 on HLA class I-mediated
immunity we have observed is not attributable to KIR2DL2
directly binding the HLA molecule whose effect is enhanced. To
test this hypothesis we first investigated whether the other group
C1 alleles had the same effect as C*08 in HTLV-1 infection.
Grouping all the C1 alleles we found no significant association
between C1 and decreased risk of HAM/TSP either in the whole
cohort or in KIR2DL2+ individuals. Similarly, there was no
relation between pvl and C1 in either ACs or HAM/TSP patients.
Analysis of the individual C1 alleles confirmed the hypothesis that
the C*08 effect we observed was not exhibited by other group C1
alleles (Tables S4 and S5).
HLA-B*54, a group Bw6 HLA allele, is not known to bind any
KIR molecule. We therefore tested whether the observed B*54
effect was attributable to C*01, which is in linkage disequilibrium
with B*54 and which encodes molecules that bind KIR2DL2. This
analysis suggested that B*54, not C*01, was the gene driving the
observed detrimental effect on HTLV-1 outcome (section 5.2 in
Text S1). This result, and the observation that no other C1 allele
shows ‘‘B*54-like’’ behaviour, indicate that, as postulated, the
interaction between B*54 and KIR2DL2 cannot be explained by
direct KIR-HLA binding.
The most frequent B*57 allele in our cohort is B*5701, which
does not bind KIR2DL2 [9]. There are therefore two ways in
which the observed interaction between KIR2DL2 and HLA-
B*57 could be attributed to ‘‘classical’’ KIR-HLA binding: either
KIR2DL2 might bind a class I HLA molecule whose encoding
gene is linked to HLA-B*57, or the effect might be due to
KIR3DL1/S1, which does bind B*57. Analysis of both these
possibilities indicated that they did not explain the KIR2DL2-B*57
effect (section 5.3 and 5.4 in Text S1).
Therefore, as hypothesised, the enhancement of C*08, B*54
and B*57–restricted immunity by KIR2DL2 is not explained by
direct binding between the respective HLA molecules and
KIR2DL2. Instead, we suggest that KIR2DL2 binds its HLA-C
ligands and indirectly modulates C*08, B*54 and B*57–restricted
T cells. Consistent with this, we found some evidence that
KIR2DL2 enhanced HLA Class I effects more strongly when it’s
stronger C1 ligands are present (section 6 in Text S1).
Other inhibitory KIR
It seems unlikely that KIR2DL2 behaves fundamentally
differently to other inhibitory KIRs. The effect of KIR2DL2 may
be most apparent because KIR2DL2 is present at informative
frequencies and its C1 and C2 ligands are ubiquitous. We
addressed the role of other inhibitory KIRs in 3 ways. We studied
Table 2. KIR2DL2 in HCV infection: KIR2DL2 enhances the protective effect of HLA-B*57 on HCV status (spontaneous clearance v
chronic infection) and, independently, on HCV viral load.
HCV status (spontaneous clearance v chronic infection)
OR in whole
cohort (p value)
KIR2DL2
Genotype
OR in stratified
cohort (p value)
HLA B*57
Allele Carriers Cohort size
0.571 (p = 0.02) + 0.403 (p = 0.007) 49 408
2 0.832 (p = 0.6) 35 374
+/+ 0.209 (p = 0.02) 16 84
2/+ 0.475 (p = 0.07) 33 324
2/2 0.832 (p = 0.6) 35 374
HCV Viral load
Difference in VL in
whole cohort (p value)
KIR2DL2
Genotype
Difference in VL in
stratified cohort (p value)
HLA B*57 Allele
Carriers Cohort size
MHCS ALIVE MHCS ALIVE MHCS ALIVE MHCS ALIVE
23.106 (p = 0.0003) 20.180 (p = 0.3) + 24.485 (p,0.0001) 20.459 (p = 0.05) 5 13 46 76
2 21.640 (p = 0.2) +0.324 (p= 0.4) 5 5 25 69
In the HCV status models an odds ratio (OR),1 indicates a protective effect (decreased odds of chronic infection), an OR.1 indicates a detrimental effect (increased
odds of chronic infection). In the viral load models the dependent variable was log10[viral load]. Cohorts were analysed separately as viral load was measured using
different assays. Two cohorts (MHCS and ALIVE) had sufficient numbers of individuals with measurements of all variables for this analysis. A difference in VL,0 indicates
a protective effect (decreased vl with the HLA allele), a difference in VL.0 indicates a detrimental effect (increased vl with the HLA allele). All models included all
variables which can act as confounders (see Methods). The impact on viral burden was considered within chronic carriers and so the observation of an impact on viral
burden is independent of the observation of an impact on status. The combined p-values of the difference in VL for the two cohorts are pcomb = 0.00003 in KIR2DL2+ and
pcomb = 0.66 in KIR2DL2-.
doi:10.1371/journal.ppat.1002270.t002
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the effect of individual inhibitory KIRs (section 4.1 in Text S1), we
investigated whether the number of inhibitory KIR:ligands had a
cumulative effect (section 7 in Text S1) and we examined the role
of the group A KIR haplotypes which are dominated by inhibitory
KIRs but do not contain KIR2DL2 (section 8 in Text S1). We
found little evidence that the other inhibitory KIRs enhanced
HLA class I-mediated immunity but this may be due to small
cohort sizes and masking by the dominant KIR2DL2 effect.
Activating KIR
We found no evidence that activating KIR were enhancing
HLA class I-restricted immunity. Haplotype B, the more
activatory KIR haplotype, enhanced HLA class I associations
but this was only true if the haplotype contained KIR2DL2
(section 8 in Text S1). We found no evidence that the cumulative
presence of activating KIR enhanced HLA class I restricted
immunity (section 4.3 in Text S1). And, as far as it was possible to
separate KIR2DL2 and KIR2DS2, which are in tight linkage
disequilibrium, the enhancement of HLA class I restricted
immunity appeared to be attributable to KIR2DL2 rather than
KIR2DS2 (section 4.2 in Text S1).
Discussion
We show that KIR2DL2 enhanced several independent HLA
class I-mediated effects in two unrelated viral infections. In
HTLV-1 infection, KIR2DL2 enhanced the protective and
detrimental effects of HLA-C*08 and B*54 respectively on disease
status. KIR2DL2 also enhanced the association between C*08 and
low proviral load in ACs and between B*54 and high proviral load
in HAM/TSP patients. Additionally, KIR2DL2 enhanced the
protective effect of HBZ binding by multiple HLA molecules.
Strikingly, on stratifying by KIR2DL2, we observed, for the first
time, a protective effect of C*08 on pvl in HAM/TSP patients and
explained the lack of impact of B*54 on pvl in ACs. In HCV
infection, KIR2DL2 enhanced the protective effect of B*57 on
spontaneous clearance and the association between B*57 and low
viral load in chronic carriers; for both clearance and viral load a
Figure 3. The impact of HLA-B*57 and KIR2DL2 on HCV viral load. In HCV infection, B*57 is associated with a reduced HCV viral load. This
protective effect is enhanced in KIR2DL2+ individuals and reduced or absent in KIR2DL2- individuals. The cohorts were analysed separately as viral
load was measured using different assays. Two cohorts, MHCS and ALIVE, had enough individuals with measurements for all factors to perform this
analysis. HIV-1 status was a significant determinant of viral load in the ALIVE cohort, including HIV status in the model as a covariate did not change
any of our conclusions (ALL p= 0.3; KIR2DL2+ p=0.05; KIR2DL2- p=0.4). Summary data from these plots is provided in Table 2. The p-values are
derived based on the regression model.
doi:10.1371/journal.ppat.1002270.g003
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progressive effect with KIR2DL2 copy number was observed. This
progressive effect is consistent with reports of an association
between KIR gene copy number and the frequency of cell-surface
expression of the respective KIR molecule [24–25].
There are two mechanisms by which KIR2DL2 could act: it
could enhance either NK-mediated or T cell-mediated immunity.
That is, NK cell killing of virus-infected cells could be altered by
KIR2DL2 expression or, alternatively, the virus-specific CD8+ T
cell response could be modified by KIR2DL2 expression (on NK
cells or T cells). Two observations indicate that it is the T cell
response that is more likely to be enhanced. First, strong binding of
HBZ viral peptides via multiple different HLA-A and B molecules
was associated with asymptomatic status [20] and this protective
effect was enhanced by KIR2DL2. KIR2DL2 is not known to bind
HLA-A or–B molecules (with the exception of B*4601 and
B*7301) [9,23,26] so it is unlikely that the enhancement of the
protective effect of binding HBZ by KIR2DL2 is due to direct
binding between KIR2DL2 and HBZ peptide in the context of
HLA-A and –B molecules. Furthermore, although NK cells
exhibit peptide dependence [27], it is hard to reconcile protein-
specificity via multiple HLA molecules with an NK cell-mediated
mechanism. Second, the KIR2DL2 enhancement could not be
explained by binding between KIR2DL2 and any of the 3 HLA
class I molecules investigated. One further observation also
suggests a T cell-mediated mechanism. Two protective genotypes
in HCV infection that are postulated to operate via innate
immune mechanisms [28] (namely a SNP upstream of IL28B and
KIR2DL3-HLA-C1) had no impact on viral load in chronic
infection [10,29]. The authors hypothesised that this was because
innate barriers offer little protection once overcome. In contrast,
the KIR2DL2/B*57 effect that we report here had a significant
impact on viral load: again, this is perhaps more consistent with
adaptive immunity.
Our results indicate that KIR2DL2 enhances HLA class 1-
restricted CD8+ T cell-mediated adaptive immunity. KIRs on
both NK cells and CD8+ T cells have been reported to shape
adaptive immunity [5-7]. Of particular interest are reports [30–33]
that inhibitory KIRs on CD8+ T cells promote the survival of a
subset of memory phenotype CD8+ ab T cells with enhanced
cytolytic potential (Tm1 [34]) by reducing activation-induced cell
death. Ugolini et al suggested that this phenomenon helps
maintain specific CD8+ T lymphocytes during chronic viral
infection [30]. Tm1 cells have been described in both HTLV-1
and HCV infections, where they constitute a minority of virus-
specific CD8+ T cells but the majority of perforin-bright cells [35–
36]. Consistent with our findings, these studies showed that the
HLA molecule that restricts the T cell whose survival is promoted
was independent of the HLA-C molecules that ligated the KIR
[30,34]. We postulate that, in the face of chronic antigen
stimulation, protective T cells survive longer if they carry KIR2DL2
and therefore exert stronger protection. Likewise, T cells restricted
by HLA alleles associated with increased disease susceptibility also
survive for longer in the presence of KIR2DL2 and so are more
detrimental (Figure 4). Hence, KIR2DL2 enhances both protective
and detrimental HLA class I associations.
Alternatively, it is known that NK cells kill activated T cells and
that this killing is reduced by inhibitory KIR [37–38]. So again, T
cells restricted by protective and detrimental HLA class I molecules
may survive longer in the presence of inhibitory KIR and thus the
protective and detrimental associations would be enhanced.
Ugolini et al proposed that inhibitory KIRs promote T cell
survival by increasing the activation threshold of T cells. This may
explain why the HLA-A*02 protective effect in HTLV-1 is not
significantly enhanced by KIR2DL2. A*02 molecules bind peptides
significantly more strongly than other alleles (section 9 in Text S1)
and the immunodominant HTLV-1 peptide Tax 11-19 is bound
exceptionally strongly. Therefore, even if the T cell activation
threshold were increased, the strength of signalling may remain
above the threshold and consequently the A*02 protective effect
cannot be enhanced.
Why does KIR2DL2 enhance T cell responses whereas the other
inhibitory KIRs apparently do not? The effect of KIR2DL2 may be
most apparent because KIR2DL2 is present at informative
frequencies and its C1 and C2 ligands are ubiquitous; i.e. unlike
the other KIR every individual carries a KIR2DL2 ligand.
It will be important to determine whether inhibitory KIRs play
a similar role in enhancing CD8+ and possibly CD4+ T cell-
mediated immunity to other pathogens and in autoimmune
disease. KIR-expressing virus-specific CD8+ T cells have been
reported in other chronic infections including HIV-1, CMV and
EBV [39-41]. Furthermore, in HIV-1 infection, high expression
alleles of an inhibitory KIR, KIR3DL1, in the context of HLA-Bw4I
have been associated with slow progression to AIDS [11]. In order
to explain protection by an inhibitory KIR the authors proposed a
model based on NK cell development. Our results suggest an
alternative explanation, i.e. that KIR3DL1 enhances protective
HLA-B-restricted responses to HIV-1.
In contrast to previous studies of KIR genotype, which
investigated the antiviral action of NK cells, we investigated the
impact of KIRs on HLA class I-mediated antiviral immunity. We
find a clear and consistent effect of KIR2DL2. The effect sizes are
striking: KIR2DL2 homozygotes with B*57 are almost 5 times
more likely to clear HCV infection spontaneously; if they fail to
clear the virus they have a viral load that is reduced by 6.5 logs.
Until now, the advantages offered by inhibitory KIRs in virus
infections have been unclear. Our data support an alternative role
in which inhibitory KIRs enhance both beneficial and detrimental
T cell-mediated immunity in persistent viral infection.
Methods
Ethics statement
The HTLV-1 cohort has been approved by the following
committees: 1) St. Mary’s Local Research Ethics Committee,
1995: title ‘‘The immunology and virology of the treatment of
HTLV-1-associated inflammatory disease’’. Approval reference
number: EC3108. 2) Kagoshima University Hospital Clinical
Research Ethics Committee: 27th May 1999. Title: ‘‘Investigation
of HAM pathomechanism: relationship between host genetic
background and clinical status of HTLV-1 infection’’. Approval
reference number: 22. All samples were taken under written
informed consent.
Cohorts
The HCV cohort consisted of four sub-cohorts: AIDS Link to
Intravenous Experience (ALIVE, N=262) [42], Multicenter
Hemophilia Cohort Study (MHCS, N=320) [43], Hemophilia
Growth and Development Study (HGDS, N=110) [44] and a UK
cohort (N= 341) [10]. 251 individuals were excluded due to
incomplete information. The cohort had 257 resolved and 525
chronic patients. HLA class I associations in three of these 4
cohorts (ALIVE, MHCS and HGDS) have previously been
reported [18].
The HTLV-1 cohort (N= 431) [14] consists of individuals
recruited in Kagoshima Japan. All individuals were of Japanese
ethnic origin and resided in Kagoshima Prefecture, Japan. The
cohort had 229 HAM/TSP patients and 202 asymptomatic
carriers.
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HLA genotyping
HLA genotyping of the HCV and HTLV-1 cohorts was
performed in previous studies [10,14,18].
HCV. Genomic DNA was amplified using locus specific
primers as described [10,18]. The resulting PCR products were
blotted onto nitrocellulose membranes and hybridized with
sequence specific oligonucleotide probes (SSO). US: alleles were
assigned according to the reaction patterns of the SSO probes,
ambiguities were resolved by sequencing analysis. UK: PCR
products were typed by direct sequencing. HLA types that were
not resolved by sequencing or which gave unusual results were also
tested by SSO typing using commercial kits (Dynal, RELI SSO,
Wirral, UK).
HTLV-1. PCR–sequence-specific primer reactions were
performed as described [45].
KIR genotyping
KIR genotyping of the HCV cohort (but not the HTLV-1
cohort) was performed previously [10].
HCV. The presence or absence of ten KIR genes (KIR2DL1,
KIR2DL2, KIR2DL3, KIR3DL1, KIR2DS1, KIR2DS2, KIR2DS3,
KIR2DS4, KIR2DS5 and KIR3DS1) was determined by PCR using
sequence specific primers as described in [46].
HTLV-1. The presence or absence of ten KIR genes
(KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR3DL1, KIR2DS2,
KIR2DS3, KIR2DS4, KIR2DS5 and KIR3DS1) was determined by
PCR using sequence specific primers [47]. 30 of the 431
individuals were not KIR genotyped due to insufficient DNA.
This method of KIR typing does not allow the direct
determination of KIR2DL2 copy number. Instead we use the allelic
nature of KIR2DL2 and KIR2DL3 at the 2DL2/2DL3 locus to infer
the number of copies of KIR2DL2.
Figure 4. Postulated mechanism: KIR2DL2 reduces clonal exhaustion of CD8+ T cells and is necessary for an effective immune
response in the face of chronic antigen stimulation. It has been demonstrated that CD8+ T cells that express inhibitory KIR have elevated
levels of Bcl-2, are less susceptible to activation induced cell death (AICD) and have a survival advantage leading to their accumulation in vitro and in
vivo [30,31]. We suggest KIR2DL2 binds its HLA-C ligands so that when the CD8+ T cell is activated by engagement of its TCR by the cognate
HLA:peptide complex the CD8+ T cell will less likely to undergo AICD. If the CD8+ T cell is restricted by a protective HLA class I molecule (e.g. B*57 in
HCV or C*08 in HTLV-1) it will survive for longer than in a person who is KIR2DL2- and its protective effects will be enhanced. Similarly, if the CD8+ T
cell is restricted by a detrimental HLA molecule (e.g. B54 in HTLV-1) it will also survive for longer and its detrimental effects will be enhanced. Of note,
the HLA molecule whose protective/detrimental effects are enhanced is the HLA molecule that binds the TCR not the HLA that binds KIR2DL2. This
postulated mechanism explains 3 striking features of our observations: i) that KIR2DL2, a receptor typically associated with innate immunity,
enhances adaptive immunity ii) that the effect cannot be explained by KIR2DL2 binding the enhanced HLA molecules directly iii) that both protective
and detrimental HLA effects are enhanced.
doi:10.1371/journal.ppat.1002270.g004
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Viral load
HCV. HCV Cohorts were analysed separately as viral load
was measured using different assays. Two cohorts (MHCS and
ALIVE) had sufficient numbers of individuals with measurements
of all variables for this analysis. For MHCS we used the median of
multiple measurements of viral load; for ALIVE, a single
measurement was available for each subject. We only analysed
viral load in patients with chronic infection, so any observed
impact on viral load is independent of an observed impact on viral
clearance.
HCV RNA was assessed by branched DNA (Quantiplex HCV
RNA 2.0 assay; Chiron Corporation) [ALIVE] or the HCV
COBAS AMPLICOR system (COBAS AMPLICOR HCV;
Roche Diagnostics) [MHCS].
HTLV-1. The HTLV-1 provirus load in peripheral blood
mononuclear cells (PBMC) was measured as described in [48].
Quantitative PCR was performed using an ABI 7700 sequence
detector (Perkin–Elmer Applied Biosystems). All DNA standards
and samples were amplified in triplicate. A standard curve was
generated by using the b-actin gene from HTLV-1-negative
PBMC and the Tax gene from TARL-2, a cell line containing a
single copy of HTLV-1 proviral DNA. We analysed viral load
separately in ACs and HAM/TSP patients, so any observed
impact on viral load is independent of any observed impact on
disease status.
Statistical analysis
HLA class I. HLA class I alleles which were significantly
associated with outcome in our cohorts and that were
independently verified (either in a large independent cohort or
on an independent outcome) were studied. For HTLV-1 there are
three such associations: HLA-A*02 and C*08 which are associated
with reduced proviral load in ACs and reduced risk of HAM/TSP
and HLA-B*54 which is associated with increased proviral load in
HAM/TSP patients and increased risk of HAM/TSP [13-14]. For
HCV there are two such associations: HLA-B*57 and C*01 which
have both been associated with increased odds of viral clearance in
two independent cohorts [17,49]. The C*01-protective effect in
HCV infection has been shown to be NK-mediated [10,28] and
therefore we did not consider it here.
KIR. We investigated KIR genes which were present at an
informative frequency. We define an informative frequency as
sufficient to detect a ‘‘moderate’’ effect size (d=0.5, [50]); this is
equivalent to at least 32 people carrying the gene and 32 not
carrying the gene. Of the KIR genes typed, 4 were present at an
informative frequency in the HTLV-I cohort (KIR2DL2, KIR2DS2,
KIR2DS3 and KIR3DS1) and 9 in the HCV cohort (KIR2DL2,
KIR2DL3, KIR3DL1, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4,
KIR2DS5 and KIR3DS1).
The effect of individual HLA class I alleles in different KIR
genetic background was investigated by stratifying the cohorts for
the absence and presence of the informative KIRs and the effect of
the already described HLA class I associations were re-evaluated
in each stratum. The impact of the HLA alleles on two response
variables was studied: 1) status (AC vs. HAM/TSP for HTLV-1
infection and resolved vs. chronic for HCV infection) and 2) viral
burden (log10[proviral load] for HTLV-1 infection and log10[-
viral load] for HCV infection). Multiple logistic regression was
used to study the variation in status and multiple linear regression
was used for the variation in viral burden. All statistically
significant confounding variables were included in the models
(HTLV-1: age and gender; HCV: HBV status, mode of infection,
SNP rs12979860 and cohort). We focused on the difference
between KIR+ and KIR- individuals in the size of the protective/
detrimental effects associated with the individual HLA class I
molecules (i.e. odds ratios and differences in viral load) rather than
p values as the latter comparison is confounded by differences in
strata sizes.
We quantified the false discovery rate for our analysis using
Monte Carlo methods. For each of the HLA associations studied,
we performed 10,000 random stratifications of the relevant (HCV
or HTLV-1) cohort with the size of the two strata being the
number of KIR2DL2+ and KIR2DL2- individuals in that cohort
and asked how many times we would see odds ratios equal to or
more extreme than we observed in the actual cohorts. The
probability of making our observations by chance is less than
p= 2610211.
Linkage disequilibrium (LD) between HLA class I alleles was
calculated using the tool available at www.hiv.lanl.gov. The LD
between KIRs was calculated based on the Chi-squared test on a
2x2 contingency table. All the reported p values are two-tailed.
Where applicable, independent p values were combined using
Fisher’s combined test. Statistical analysis was performed using R
v2.9.2.
Epitope prediction
The binding strength of HLA class I molecules to viral proteins
was assessed using epitope prediction software. Prediction of T cell
class I epitopes is now highly accurate and algorithms can achieve
accuracy of up to 94% [51]. In this study we use the epitope
prediction software Metaserver [21] (http://web.bioinformatics.ic.
ac.uk/metaserver).
Rank measure for predicted epitopes
We used the rank measure technique [52] in which the strength
of an allele’s preference for a particular protein is quantified by
ranking the strength of binding of the top binding peptide from the
protein of interest amongst the strength of binding of peptides
from the entire proteome to that allele. Specifically, we split the
HTLV-1 proteome into overlapping nonamers offset by a single
amino acid and predicted a binding affinity score for each
nonomer. For each allele we rank all nonamers from the proteome
from the weakest to strongest predicted binding scores. This
produces a list of rank values for each protein to that particular
allele that quantifies the binding relationship between that allele
and the protein. We then invert the rank so the bigger 1/rank, the
stronger the preference of the allele for the protein; the logarithm
of this measure is plotted on the y axis of Figure 2 as ‘‘HBZ
binding score’’. Each individual therefore contributes up to 4
values (alleles for which no predictive algorithms were available
were excluded from the analysis). Binding scores were compared
between ACs and HAM/TSP patients using the Wilcoxon rank
sum test and reported both as separate p values for HLA-A and B
molecules and combined (since we found no evidence to reject the
null hypothesis that the HBZ binding score of an individual’s A
and B molecules was independent, spearman correlation= 0.05
p= 0.5). The median difference in binding score is the median of
the difference of average HBZ binding between ACs and HAM/
TSP patients expressed as a percent of the AC binding score for
HLA-A and –B molecules.
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